We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Cyberkinetics Neurotechnology Systems has obtained 510(k) clearances for its
NeuroPort Cortical Microelectrode Array and NeuroPort Neural Signal Processor
(NSP).
BioElectronics, a developer of advanced, disposable, therapeutic medical devices,
announced that it has entered into an agreement with PD-Rx for PD-Rx to distribute
ActiPatch Therapy to physicians and healthcare providers that participate in
the PD-Rx programs.
CardioTech International announced that CorNova has successfully completed its
Series A financing of $3 million, enabling CorNova to continue executing its
business plan.
Xilas Medical said that the National Institutes of
Health (NIH) awarded the local company an $880,000 grant to conduct Phase II
clinical trials on its TempTouch RM infrared temperature remote-monitoring device.
International Isotopes announced completion of a four-year Cobalt Source Recycle
Agreement with Alpha-Omega Services (AOS) of Bellflower, Calif. AOS designs
and develops radioactive sources and accessories for the brachytherapy market.
Covalon Technologies announced that it has responded to the FDA's request for
further information regarding the company's 510(k) premarket notification for
its ColActive wound dressing.
Sweden's Elekta AB said it completed the $250 million acquisition of Mountain
View, Calif.-based IMPAC Medical Systems, following approval of the transaction
by IMPAC's stockholders.
ThermoGenesis announced that the company and Biomet reached agreement for the
company to supply Biomet's subsidiary, Cell Factor Technologies, with disposable
kits that produce stable, activated thrombin from the patients own blood in
less than 30 minutes.
Fisher Scientific International completed its sale of Atos Medical AB, a manufacturer
of ear, nose and throat medical devices with 2004 sales totaling $35 million,
to Nordic Capital for $110 million in cash.
Gen-Probe announced that it has received a tentative award in its arbitration
with Bayer HealthCare concerning the parties' collaboration for the development
and sale of nucleic acid diagnostic tests for viral organisms.